Literature DB >> 9701399

Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression.

I Brotherick1, C N Robson, D A Browell, J Shenfine, M D White, W J Cunliffe, B K Shenton, M Egan, L A Webb, L G Lunt, J R Young, M J Higgs.   

Abstract

Transition from a normal to a cancerous state is marked by alterations in the cytoskeletal structure of those cells involved. We have examined such changes to determine if these transitions are markers of disease progression. Cytokeratin (CK) protein and messenger RNA (mRNA) expression were examined in malignant and benign breast tissues. Flow cytometric results demonstrated a significant correlation between cytokeratin protein expression detected by 5D3 antibody, specific for cytokeratins 8, 18, and 19 and axillary node metastasis (P = 0.01). A threshold of positivity of 338,000 molecules/cell was determined and reflected the wide range in cytokeratin levels expressed by normal or benign tissues. Examination of cytokeratins 8, 18, and 19 revealed a consistent pattern of expression with respect to tumor grade. Only cytokeratin 19 showed significant correlation with increasing tumor size (P = 0.006). mRNA expression for cytokeratin 8 was significantly higher in node-positive compared with node-negative disease (P = 0.02). Cytokeratin 18 mRNA levels were significantly lower in both node-negative (P = 0.03) and node-positive (P = 0.02) patients when compared with benign samples. Increased levels of cytokeratin 18 mRNA showed an inverse relationship with protein expression (P = 0.05). The results indicate that cytokeratin expression in breast cancer may be associated with tumor progression. Furthermore, the alteration in the expression of individual cytokeratins deserves further investigation to determine the consequences of these changes with respect to cellular function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701399

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  12 in total

1.  Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties.

Authors:  M J Page; B Amess; R R Townsend; R Parekh; A Herath; L Brusten; M J Zvelebil; R C Stein; M D Waterfield; S C Davies; M J O'Hare
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Identification of differentially expressed genes in isogenic highly metastatic and poorly metastatic cell lines of R3230AC rat mammary adenocarcinoma.

Authors:  H Günes; S A Carlsen
Journal:  Cell Prolif       Date:  2003-12       Impact factor: 6.831

3.  Widespread, exceptionally high levels of histone H3 lysine 4 trimethylation largely mediate "privileged" gene expression.

Authors:  Li Chen; Pervez Firozi; Michelle Barton; Nancy Smyth Templeton
Journal:  Gene Expr       Date:  2007

Review 4.  Protein biomarkers for subtyping breast cancer and implications for future research.

Authors:  Claudius Mueller; Amanda Haymond; Justin B Davis; Alexa Williams; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2018-01-03       Impact factor: 3.940

5.  Cytoskeletal and extracellular matrix proteins as markers for metastatic triple negative breast cancer.

Authors:  Mohammed Elimam Ahamed Mohammed; Nuha Mohammed Elhassan
Journal:  J Int Med Res       Date:  2019-10-11       Impact factor: 1.671

6.  Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement.

Authors:  A P Taylor; E Leon; D M Goldenberg
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

7.  Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients.

Authors:  Yanan Kong; Junye Wang; Wanli Liu; Qiaolun Chen; Juan Yang; Weidong Wei; Mingqing Wu; Lu Yang; Xinhua Xie; Ning Lv; Jiaoli Guo; Laisheng Li; Jie Gao; Xiaoming Xie; Shuqin Dai
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

8.  Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance.

Authors:  Valérie Choesmel; Jean-Yves Pierga; Claude Nos; Anne Vincent-Salomon; Brigitte Sigal-Zafrani; Jean-Paul Thiery; Nathalie Blin
Journal:  Breast Cancer Res       Date:  2004-07-29       Impact factor: 6.466

9.  Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.

Authors:  B Nakata; T Takashima; Y Ogawa; T Ishikawa; K Hirakawa
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

10.  The expression of CK-19 gene in circulating tumor cells of blood samples of metastatic breast cancer women.

Authors:  Setareh Soltani; Fariborz Mokarian; Mojtaba Panjehpour
Journal:  Res Pharm Sci       Date:  2015 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.